Myelodysplastic/Myeloproliferative Syndromes

 

Treosulfan + Fludarabine + TBI for Allo HCT for AML and MDS (FHCRC-2272)
Conditioning With Treosulfan, Fludarabine And Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Investigator: Boglarka Gyurkocza, MD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD);    Status: Recruiting;   Study ID: NCT00860574

Clofarabine, Cytarabine, and G-CSF for Newly Diagnosed Acute Myeloid Leukemia or Advanced MDS (7144)
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Under Age 60 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS);    Status: Recruiting;   Study ID: NCT01101880

Bendamustine Hydrochloride and Idarubicin for Previously Untreated AML or MDS (2413)
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS)

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Recruiting;   Study ID: NCT01141725

Pomalidomide for Myeloproliferative Neoplasms (2465)
A Phase-3, Multi-Center, Randomized, Doubleblind, Placebo-Controlled, Parallel-Group Study To Compare Efficacy And Safety Of Pomalidomide In Subjects With Myeloproliferative Neoplasm, Associated Myelofibrosis And Red Blood Cell-Transfusiondependence

Investigator: Joachim Deeg, MD;   Conditions: Hematologic Malignancies; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT01178281